BRAF and non-small cell lung carcinoma: Auliac previously reported that among the 46 advanced NSCLC patients with the BRAF V600E mutation registered in France between 2012 and 2014, those with the BRAF V600E mutation had 8.7 months of PFS with first-line therapy and 4.1 months with second-line therapy (36).